Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Alphamab Publishes Trial Data on Bispecific for Non-Small Cell Lung Cancer

publication date: Mar 22, 2024

Suzhou Alphamab Oncology reported positive data from a Phase II trial of KN046, its anti-PD-L1/CTLA-4 bispecific antibody plus chemotherapy as a first-line treatment for metastatic non-small cell lung cancer (NSCLC). The bispecific candidate is engineered to target the tumor microenvironment with high PD-L1 expression and clearing of Treg cells. Alphamab is conducting about 20 clinical trials of KN046 for over 10 indications, including NSCLC, pancreatic cancer, thymic cancer, HCC, ESCC and TNBC. The trial results were published online in Cell Reports Medicine. More details....

Stock Symbol: (HK: 9966)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital